Compare BioNTech SE - ADR (BNTX) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Microchip Technology Inc. — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Microchip Technology Inc. trades at $87.97 (market cap $47.30B). The key difference: Microchip Technology Inc. is far larger — about 2.1× BioNTech SE - ADR's market cap, and Microchip Technology Inc. pays a 2.09% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MCHP | |
|---|---|---|
Market Cap | $22.86B | $47.30B |
Sector | Health | Technology |
52-Week High | $119.34 | $102.97 |
52-Week Low | $83.89 | $49.02 |
Enterprise Value | $6.53B | $52.60B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Microchip Technology (MCHP) trades at $84.23, down 4.92% in the last session, with a bearish technical signal and support near $81. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, while revenue declined to $4.40B. Analyst consensus remains strongly bullish with a $113.33 price target, supported by positive news on AI and aerospace demand.
MCHP faces near-term pressure from weak profitability and high debt, but long-term growth is supported by AI, data center, and aerospace exposure. Risks include cyclical semiconductor demand and execution challenges, yet institutional sentiment and recent product launches suggest potential recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
